This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.